PharmaFocus Today – Page 5 – media

The world’s first Simeglutide chewable gummy candy has been launched!

Recently, Eden announced the launch of Simeglutide chewable gummies, the world’s first Simeglutide chewable gummies. This pioneering GLP-1 gummy provides the same active ingredients as compound semaglutide. Eden aims to provide the benefits of GLP-1 drugs such as semaglutide in a convenient form without needle injection, and promote personalized medication for patients. According to the information disclosed on Eden’s official website, the price of Simeglutide chewable gummies includes three options: Eden President Josh Khan said, “At Eden, we are committed to making transformative healthcare services more convenient and accessible. Through this pioneering gummy candy, we eliminate barriers such as needles and discomfort, allowing individuals to explore personalized care plans with healthcare providers to achieve their health goals in a way that suits their lives. This gummy candy is not only a pioneering product in the field, but also meets the growing demand for more convenient alternatives to traditional medicines. Research ...
- Source: drugdu
- 54
- January 10, 2025
Ascentage Pharmaceuticals “advances rapidly”

Ascendance Pharmaceuticals has achieved great success in 2024. The sales of the first commercialized product have been soaring, and the BD transaction with Takeda Pharmaceutical has enabled the company to turn losses into profits for the first time. The pipeline under development is progressing smoothly… Under multiple favorable factors, Ascentage Pharmaceuticals’ share price in 2024 has risen from HK$27 per share at the beginning of the year to HK$45.45 per share, an increase of 68%. If calculated from the low point in April, it has risen by 195%, becoming the “dark horse” among pharmaceutical stocks this year. At the same time, Ascentage Pharmaceuticals has also started the IPO process in the US stock market. Recently, Ascentage Pharmaceuticals’ listing filing for IPO in the US has been confirmed by the China Securities Regulatory Commission, and it plans to issue no more than 33,739,347 common shares and list on the Nasdaq Stock ...
- Source: drugdu
- 49
- January 10, 2025
Now is the best time for influenza vaccination

Recently, China CDC released the latest national sentinel surveillance of acute respiratory infectious diseases. The analysis of the monitoring results shows that, at present, acute respiratory infectious diseases are generally showing a continuous upward trend, and the trends of infection caused by different pathogens are different. Influenza is generally in the seasonal epidemic period, and the positive rate of influenza virus is rising rapidly; among them, the positive rate of influenza virus in outpatient and emergency influenza-like cases nationwide has increased by 6.2% compared with last week. The positive pathogens detected in the outpatient and emergency departments of sentinel hospitals are mainly influenza virus, human metapneumovirus, and rhinovirus, and the positive pathogens detected in hospitalized severe acute respiratory infection cases are mainly influenza virus, Mycoplasma pneumoniae, and human metapneumovirus. In other words, influenza is one of the most important pathogens in both outpatient and emergency cases and inpatient severe cases. ...
- Source: drugdu
- 55
- January 10, 2025
Who will win the world’s first PROTAC drug?

In recent years, the biopharmaceutical market has shown a trend of rapid growth, in which the research and development of innovative drugs has become the focus of attention. As an innovative drug development model, target protein degradation technology has achieved remarkable results in preclinical research. Here, the author combines market trends, research and development progress and other factors to predict the PROTAC drugs that are expected to be approved in 2025, and looks forward to the future development prospects of this technology. Three drugs are making rapid progress Up to now, protein degraders have made significant progress in clinical research. According to incomplete statistics, a total of 36 protein degradation agents have entered the clinical stage around the world, and the total number of protein degradation R&D pipeline projects worldwide has exceeded a thousand. Among the 10 PROTACs that are expected to be approved, the indications are concentrated in cancer, ...
- Source: drugdu
- 49
- January 10, 2025
Haier Bio terminate the planning of absorption merger with Shanghai Laishi

On the evening of January 6, 2025, Qingdao Haier Biomedical Co., Ltd. (“Haier Bio”, 688139.SH) and Shanghai Laishi Blood Products Co., Ltd. (“Shanghai Laishi”, 002252.SZ) announced the termination of the planning for a major asset restructuring and the resumption of the company’s stock trading. They have decided to terminate the substantial asset restructuring plan for Haier Bio to absorb and merge with Shanghai Laishi. At the same time, both companies issued announcements regarding a proposal from the chairman to repurchase shares. Haier Bio’s share repurchase plan totals between 100 million to 200 million yuan, while Shanghai Laishi’s totals between 250 million to 500 million yuan. The stocks of both companies will resume trading at the opening on Tuesday, January 7, 2025. According to the announcements from both companies, to enhance investor confidence and based on strong confidence in the future development of Haier Bio and Shanghai Laishi, as well as ...
- Source: drugdu
- 50
- January 10, 2025
Pianzaihuang settled in the biopharmaceutical cluster in Daxing District, Beijing, with an industrial scale of 73.7 billion yuan

The reporter learned from the “Two Sessions” in Daxing District that as the “main battlefield” for the development of Beijing’s biopharmaceutical industry, Daxing District will aggregate the biopharmaceutical ecosystem and achieve remarkable results in 2024. China Medicine Valley has been selected as a “Chinese characteristic biopharmaceutical industry park”, and the six centers directly under the National Medical Products Administration have been unveiled and put into operation. Capital Medical University has started construction, and 10 chain leading enterprises such as Pianzaihuang have flocked to accelerate the construction of a comprehensive biopharmaceutical cluster, with an industrial scale of 73.7 billion yuan. Recently, the neon lights of the Pien Tze Huang Beijing Innovation and Research Base building located in the Xingchuang International Center in Daxing District began to light up. It is reported that Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (hereinafter referred to as “Pien Tze Huang Company”) is steadily advancing its ...
- Source: drugdu
- 68
- January 9, 2025
Zhengye Biotechnology, the first US listed company in Jilin Province, has landed on NASDAQ

On the evening of January 7th Beijing time, Jilin Zhengye Biological Products Co., Ltd. (referred to as “Zhengye Biotechnology”) successfully went public on the NASDAQ Stock Exchange in the United States, filling the gap for Jilin Province’s enterprises to go public in the United States. Zhengye Biotechnology is an animal vaccine manufacturer whose main business includes research and development, manufacturing, sales, and technical services of animal vaccines. The company is located in Jilin City, Jilin Province, China. Its predecessor was Harbin Veterinary Biopharmaceutical Factory of the Ministry of Agriculture, which relocated to Jilin City in 1970. It is one of the earliest veterinary biopharmaceutical enterprises directly under the Ministry of Agriculture in China, with a history of more than 50 years. In 2004, Zhengye Biotechnology was restructured from Jilin Province Biological Products Factory and is now a privately-owned joint-stock enterprise. The company’s products cover four types of animal vaccines, including ...
- Source: drugdu
- 63
- January 9, 2025
Two medical devices have entered the priority approval channel

According to the China Medical Device Innovation and Priority Approval Database, in December 2024, two medical devices entered the priority approval green channel in public announcements issued by local drug regulatory authorities across the country. They are: the disposable electronic endoscopic thoracoscopic laparoscopic catheter from Fujian Zhide Medical Technology Co., Ltd. (hereinafter referred to as Fujian Zhide), and the cognitive impairment assisted diagnosis and rehabilitation software from Hainan Boya Health Technology Co., Ltd. (hereinafter referred to as Hainan Boya). Fujian Zhide: Focusing on Endoscopy Fujian Zhide was established in April 2022 and is a company dedicated to the research and manufacturing of electronic endoscopic medical devices. The disposable 4K electronic endoscope technology developed by the research and design team of Fujian Zhide Optics has received widespread attention. This technology is both safe and convenient, not only greatly reducing the infection rate and improving cost-effectiveness, but also adapting to grassroots needs. ...
- Source: drugdu
- 72
- January 9, 2025
Innovent has made a good start

At the beginning of the new year, Innovent Biologics brought the first good news of going overseas. Recently, Innovent Biologics and Roche reached a global exclusive cooperation and licensing agreement on the new generation of DLL3 antibody-drug conjugates. Innovent Biologics granted Roche the exclusive rights to the global development, production and commercialization of IBI3009. The two parties will jointly be responsible for the early development of the ADC candidate drug, and Roche will be responsible for subsequent clinical development. Innovent Biologics will receive a total transaction amount of US$1.08 billion (including an initial payment of US$80 million and potential development and commercialization milestone payments of up to US$1 billion, as well as sales commissions). Just a few days ago, Hengrui Medicine also reached a licensing cooperation for DLL3 ADC drugs. Hengrui Medicine licensed the overseas rights of SHR-4849 to IDEAYA Biosciences of the United States for a total amount of ...
- Source: drugdu
- 62
- January 9, 2025
A battle for survival for BTK inhibitors?

Recently, Sanofi’s Rilzabrutinib was applied for listing in China for the treatment of immune thrombocytopenia (ITP). This means that the “six-strong competition” pattern in the domestic BTK inhibitor market has begun to emerge. The autoimmune BTK inhibitor market is now a place of chaos. Before Sanofi’s Rilzabrutinib was applied for listing, five BTK inhibitors had been approved in China, including AbbVie/Johnson & Johnson’s ibrutinib, AstraZeneca’s acotinib, BeiGene’s zanubrutinib, Innovent’s obeticholic steroids, and Eli Lilly’s Pirtobrutinib. The indications are mainly concentrated in hematological tumors, and only a few have been approved for autoimmune diseases. It can be seen that focusing on autoimmune indications has become a differentiated breakthrough path. Sanofi’s Rilzabrutinib is the embodiment of this strategy. The strong players in the autoimmune track are not only AbbVie and Johnson & Johnson, but also Sanofi’s strength should not be underestimated. For example, the ace product Dupixent (dupixentumab) is a “super blockbuster” ...
- Source: drugdu
- 71
- January 9, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.